ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.
Alpheus Medical provides a novel sonodynamic therapy platform targeting solid body cancers. Alpheus Medical also provides a non-invasive drug-device combination for outpatient treatment of recurrent glioblastoma multiforme (rGBM).
Scout Bio, Inc. researches and develops one-time therapies for major chronic pet health conditions using veterinary biotechnology and gene therapy. It offers therapies for anemia associated with chronic kidney disease (CKD) in cats. The company offers pet therapeutics, including small molecular drugs, protein therapies, and gene therapies. Scout Bio, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
iECURE is a biotechnology company focused on developing gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. The company employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted therapeutic interventions without being limited by specific genetic mutations. Its initial programs concentrate on addressing metabolic "loss of function" disorders, which often have significant unmet medical needs. Through its innovative approach, iECURE aims to provide effective treatments for devastating diseases that currently lack viable options.
ArriVent Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative treatments for cancer. The company aims to address unmet medical needs by leveraging its team's extensive experience in drug development. ArriVent is advancing its lead candidate, furmonertinib, along with a pipeline of novel therapeutics, including next-generation antibody-drug conjugates. The company's initial emphasis is on solid tumors, reflecting its commitment to improving outcomes for cancer patients through differentiated medicines.
Century Therapeutics, Inc. is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-based therapies for cancer treatment. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company aims to create allogeneic living drugs that specifically target both hematologic and solid tumors. By utilizing iPSCs, Century Therapeutics can engineer immune effector cells through multiple rounds of cellular modification, producing master cell banks that can be expanded and differentiated for therapeutic use. Their innovative approach incorporates advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, along with Allo-Evasion technology, which helps prevent rejection by the host immune system. These advancements position Century Therapeutics to enhance the effectiveness and accessibility of cancer treatments.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.
Private Equity Round in 2017
TELA Bio, Inc. is a medical technology company based in Malvern, Pennsylvania, that specializes in the design, development, and marketing of tissue reinforcement materials aimed at addressing unmet needs in soft tissue reconstruction. Founded in 2012, the company offers a range of products under the OviTex brand, including OviTex Reinforced Tissue Matrix for hernia repair and abdominal wall reconstruction, as well as OviTex PRS Reinforced Tissue Matrix for plastic and reconstructive surgery. Additionally, TELA Bio provides OviTex products specifically designed for laparoscopic and robotic surgical procedures, which utilize a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber. The company's marketing efforts are primarily conducted through a direct sales force operating mainly in the United States.
Realm Therapeutics is a biopharmaceutical company based in Malvern, Pennsylvania, focused on leveraging proprietary technologies to enhance health outcomes for adults and children. Initially engaged in developing therapies for immune-mediated diseases, the company's drug development efforts are centered on creating small molecule therapies aimed at inflammatory diseases, with applications in dermatology and ophthalmology, as well as potential use in various other conditions. Founded in 2016 and previously known as PuriCore plc, Realm Therapeutics currently operates as a subsidiary of ESSA Pharma Inc. The company is exploring opportunities for investment, partnerships, or acquisitions to further its capabilities in the life sciences sector.
Unilife is a U.S.-based medical device and technology company that specializes in designing, developing, and manufacturing innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that features smart, reusable auto-injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies packaged in standard prefilled barrels, catering to the needs of pharmaceutical and biotechnology companies that produce injectable biologics, drugs, and vaccines. Unilife's focus on differentiated delivery systems aims to improve patient experiences and outcomes in medication administration.
Unilife is a U.S.-based medical device and technology company that specializes in designing, developing, and manufacturing innovative delivery systems for injectable drugs and vaccines. The company has created a drug delivery platform that features smart, reusable auto-injectors, allowing patients to control the speed of injection. This technology enhances the delivery of therapies packaged in standard prefilled barrels, catering to the needs of pharmaceutical and biotechnology companies that produce injectable biologics, drugs, and vaccines. Unilife's focus on differentiated delivery systems aims to improve patient experiences and outcomes in medication administration.
Iroko Pharmaceuticals, LLC is a specialty pharmaceutical company based in Philadelphia, Pennsylvania, focused on developing and commercializing innovative pharmaceutical products for pain management. Founded in 2007, the company markets a range of prescription pain medications, including Indocid, Aldomet, TIVORBEX, ZORVOLEX, and VIVLODEX, which are designed to address various pain management needs, particularly for patients with osteoarthritis and acute pain. Iroko utilizes proprietary technology to formulate lower-dose nonsteroidal anti-inflammatory drugs (NSAIDs), improving therapeutic options for patients. The company has established a robust distribution and sales network, extending its reach to more than 40 countries, and aims to enhance healthcare by revitalizing existing medications through new applications and geographic markets.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.